|
|
Article: Serono Enlists Marketing Muscle' Of Pfizer In $200M Rebif Alliance.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Serono SA is teaming up with Pfizer Inc. to co-promote the multiple sclerosis drug Rebif in the United States, which will position Rebif directly against Biogen Inc.'s powerhouse drug Avonex.
With the marketing agreement, Pfizer gave Serono a $200 million up-front fee. The companies said they would share all commercialization and development costs, and Pfizer will receive "commissions on sales," said Deborah Brown, executive vice president of neurology for Serono Inc., the Rockland, Mass.-based U.S. arm of Serono SA, of Geneva.
Brown said the companies aren't revealing additional financial details about the agreement.
"We ...
Related newspaper, magazine, and journal articles:
|
|
Article: MEGABIOS, GENEMEDICINE AGREE TO `STRATEGIC MERGER' THAT POOLS ...
BIOWORLD Today;
October 27, 1998 ;
700+ words
... ... percent, or $0.281. McGraw told BioWorld Today the move is one of the few "strategic ... into GeneMedicine," Weintraub told BioWorld Today. "This merger allows us to simplify ... up relatively early," Waldron told BioWorld Today. "This merger announcement is the ...
|
|